Department of Gastroenterology, Key Laboratory of Gut Microbiota Translational Medicine Research, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Gastroenterology, Beijing Jishuitan Hospital, Beijing, China.
J Dig Dis. 2020 Aug;21(8):445-453. doi: 10.1111/1751-2980.12912.
To explore the changes in microbial composition and the corresponding impact after lactitol treatment in constipated patients.
Altogether 29 consecutive outpatients diagnosed with chronic constipation from three centers were recruited and stratified based on their history of diabetes mellitus. All patients were administered with oral lactitol for 2 weeks, and a symptoms diary of constipation was recorded. Fecal samples were collected before and after lactitol treatment, and were analyzed by 16S rRNA sequencing and real-time polymerase chain reaction (PCR) to detect gut microbiota.
Twenty patients with diabetes mellitus and nine without, all with chronic constipation, were enrolled in this study. After 2-week administration of lactitol, their subscale scores and constipation symptoms significantly decreased (P < 0.05). An analysis of fecal flora using 16S rRNA sequencing found an increasing trend of abundance of Bifidobacterium in the post-lactitol group (P = 0.08). Actinobacteria, Actinobacteria, Bifidobacteriales, Bifidobacteriaceae and Bifidobacterium were significantly more abundant after lactitol administration. Real-time PCR showed significantly high DNA copy numbers of Bifidobacterium after lactitol treatment (1.39 × 10 vs 2.74 × 10 copies/μL, P = 0.01). The results of 16S rRNA sequencing and real-time PCR illustrated an increasing trend of Bifidobacterium in both patients with and without diabetes. In addition, Bifidobacterium was negatively correlated with constipation subscale scores.
Alterations in fecal flora composition after lactitol supplementation, especially in terms of an increasing trend of Bifidobacterium, alleviated constipation symptoms. Lactitol may be a promising prebiotic candidate for patients with constipation, regardless of diabetes mellitus.
探讨乳果糖治疗后便秘患者肠道微生物组成的变化及其相应影响。
从三个中心招募了 29 名连续的被诊断为慢性便秘的门诊患者,并根据其糖尿病病史进行分层。所有患者均口服乳果糖治疗 2 周,并记录便秘症状日记。在乳果糖治疗前后采集粪便样本,通过 16S rRNA 测序和实时聚合酶链反应(PCR)分析检测肠道微生物群。
本研究共纳入 20 例糖尿病合并慢性便秘患者和 9 例非糖尿病合并慢性便秘患者。乳果糖治疗 2 周后,患者的亚量表评分和便秘症状明显下降(P<0.05)。通过 16S rRNA 测序分析粪便菌群发现,治疗后双歧杆菌的丰度呈上升趋势(P=0.08)。乳果糖治疗后,厚壁菌门、放线菌门、双歧杆菌目、双歧杆菌科和双歧杆菌的丰度显著增加。实时 PCR 显示,乳果糖治疗后双歧杆菌的 DNA 拷贝数显著升高(1.39×10 拷贝/μL 比 2.74×10 拷贝/μL,P=0.01)。16S rRNA 测序和实时 PCR 的结果均表明,糖尿病患者和非糖尿病患者的双歧杆菌均呈上升趋势。此外,双歧杆菌与便秘亚量表评分呈负相关。
乳果糖补充后粪便菌群组成发生改变,尤其是双歧杆菌呈上升趋势,缓解了便秘症状。乳果糖可能是便秘患者有前景的益生元候选药物,与糖尿病无关。